Lorraine Flet-Berliac

Lorraine Flet-Berliac

Auto-generated profile, based on publicly available information

Lorraine Flet-Berliac

Pediatric Neurology Departement, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University Hospitals, Bicêtre Hospital, and Paris-Saclay University, Le Kremlin-Bicêtre

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2022 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
LFLorraine Flet‐Berliac
Lorraine Flet‐Berliac
NTNicolas Tchitchek
Nicolas Tchitchek
ALAnne Lépine
Anne Lépine
AFAnca Florea
Anca Florea
HMHélène Maurey
Hélène Maurey
KDKumaran Deiva
Kumaran Deiva

1 March 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
MMMaxime Mazowiecki
Maxime Mazowiecki
LFLorraine Flet-Berliac
Lorraine Flet-Berliac
JRJulia Roux
Julia Roux
ALAnne Lépine
Anne Lépine
PCPascale Chretien
Pascale Chretien
KDKumaran Deiva
Kumaran Deiva
Anti-NMDAR encephalitis (NMDARE) is a severe neurologic condition, and recently, the NMDAR Encephalitis One-Year Functional Status (NEOS) score has emerged as a 1-year prognostic tool. This study aimed to evaluate NEOS score and biomarker (neurofilament light chains [NfL], total-Tau protein, glial fibrillary acidic protein, and serum cytokines) correlation with modified Rankin Scale (mRS), cognitive impairment, and clinical recovery in pediatric NMDARE over 2 years. In this French multicenter observational study, 104 pediatric patients with NMDARE were followed for a minimum of 2 years. Clinical data and serum/plasma samples were collected. Biomarker levels, measured using electroluminescence mesoscale discovery (MSD) S-PLEX, were compared between patients and controls and assessed for correlations with disease activity, mRS, cognitive/language impairment, and recovery status at 2 years. At a median follow-up of 39.5 months, 68 percent of patients had unfavorable recovery and 54% had significant cognitive impairment. Both outcomes were strongly associated with younger age at diagnosis (OR 6.10 [1.91-27.3] p < 0.01 and 5.69 [1.46-27.7] p = 0.02, respectively). A higher NEOS score was significantly correlated with increased cognitive impairment (OR 2.53 [1.52-4.21], p < 0.001), higher mRS scores (OR 2.12 [1.34-3.57], p < 0.01), and unfavorable recovery at 2 years (OR 2.00 [1.30-3.06], p = 0.015). Elevated NfL levels were significantly associated with unfavorable recovery (OR 3.62 [1.29-10.9] p = 0.012) and severe cognitive impairment (OR 3.77 [1.38-10.9] p = 0.012) at 2 years. The combined area under the curve (AUC) for NfL and NEOS was significantly higher than the AUCs of NEOS and NfL alone (p = 0.01). The NEOS score strongly predicts long-term outcomes in NMDARE, with its predictive value extending beyond the first-year mR prediction. NfL levels at disease onset seem to improve accuracy in predicting poor outcomes, providing valuable information for treatment decisions and future clinical trials.